NETWORK META-ANALYSIS DESIGN CONSIDERATIONS IN A COMPLEX AND RAPIDLY EVOLVING LANDSCAPE: A CASE STUDY IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

被引：0
|
作者：
Popoff, E. [1 ]
Lozano-Ortega, G. [1 ]
Varol, N. [2 ]
Yuan, Y. [3 ]
Penrod, J. R. [3 ]
Goring, S. M. [1 ]
机构：
[1] Broadst HEOR, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN275
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)
    Afonso-Afonso, F. J.
    Amenedo Gancedo, M.
    Areses Manrique, M. C.
    Campos Balea, B.
    Casal Rubio, J.
    Fernandez-Nunez, N.
    Firvida Perez, J. L.
    Garcia Gonzalez, J.
    Lazaro Quintela, M.
    Leon-Mateos, L.
    Ruiz-Banobre, J.
    Perez Parente, D.
    Crama, L.
    Ruiz Gracia, P.
    Santome Couto, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 43 - 43
  • [42] Network Meta-Analysis of First-Line and Maintenance Regimens in EGFR Mutated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    De Lima Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1224 - S1225
  • [43] Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung cancer: A network meta-analysis
    Liu, Liyan
    Yan, Yilong
    Wang, Yuqiao
    Li, Ziming
    Yang, Li
    Yu, Kefu
    Zhao, Zhigang
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [44] Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis
    Liu, Jie
    Li, Chengming
    Seery, Samuel
    Yu, Jinming
    Meng, Xue
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [45] Identifying Optimal First-Line Interventions for Advanced Non-Small Cell Lung Carcinoma According to PD-L1 Expression: A Systematic Review and Network Meta-Analysis
    Liu, J.
    Yu, J.
    Meng, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E131 - E132
  • [46] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G. W.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
  • [47] Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany
    Snee, M.
    Cheeseman, S.
    Levick, B.
    Hall, G.
    Rohde, G.
    Stratmann, J.
    Wolf, A.
    van Gils, C.
    Griner, R.
    Mahmood, A.
    Niklas, N.
    Divan, H. A.
    Krishna, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S52 - S53
  • [48] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Jaime, B. Moreno
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
  • [49] Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
    Wu, Fang
    Tian, Wentao
    Cao, Chenghui
    Ke, Jiawen
    Tan, Nuopei
    Cai, Yuwen
    Zeng, Yue
    Pan, Yue
    Liu, Xiaohan
    Zhao, Lishu
    Shu, Long
    Liu, Junqi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
12345